Amgen Inc (AMGN)vsEnbridge Inc (ENB)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
ENB
Enbridge Inc
$53.59
-0.74%
ENERGY · Cap: $116.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Enbridge Inc generates 75% more annual revenue ($65.19B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 11.5%. AMGN appears more attractively valued with a PEG of 2.18. ENB earns a higher WallStSmart Score of 63/100 (C+).
AMGN
Buy62
out of 100
Grade: C+
ENB
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Margin of Safety
+4.6%
Fair Value
$54.02
Current Price
$53.59
$0.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Earnings expanding 294.9% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Weak financial health signals
Expensive relative to growth rate
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : ENB
The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : ENB
The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.
Key Dynamics to Monitor
AMGN profiles as a mature stock while ENB is a value play — different risk/reward profiles.
ENB carries more volatility with a beta of 0.79 — expect wider price swings.
ENB is growing revenue faster at 5.9% — sustainability is the question.
AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
ENB scores higher overall (63/100 vs 62/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Enbridge Inc
ENERGY · OIL & GAS MIDSTREAM · USA
Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?